Table 2 Evaluation of cytotoxicity of some chosen synthesized compounds against hepatocellular carcinoma cells lines (HepG-2)
Sample conc. (µg ml−1) | Cell viability (%) | |||||||
|---|---|---|---|---|---|---|---|---|
4a | 6a | 7a | 9a | 10a | 13a | 14a | Vinblastine standard | |
50.000 | 23.34 | 30.79 | 34.92 | 37.26 | 19.85 | 39.61 | 28.60 | 15.12 |
25.000 | 32.67 | 40.42 | 43.43 | 48.67 | 24.57 | 52.16 | 39.09 | 17.33 |
12.500 | 41.82 | 52.87 | 56.33 | 61.15 | 35.87 | 66.03 | 44.88 | 24.18 |
6.250 | 60.09 | 69.32 | 61.38 | 68.71 | 52.49 | 73.52 | 62.94 | 46.87 |
3.125 | 72.57 | 84.17 | 86.89 | 88.34 | 61.22 | 89.56 | 76.14 | 55.18 |
1.560 | 86.53 | 94.37 | 97.09 | 98.03 | 78.86 | 99.12 | 88.25 | 73.98 |
0.000 (DMSO) | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |